Zydus Cadila gets tentative USFDA nod for diabetes drug
Drug firm Zydus Cadila on Friday said it has received tentative approval from the US health regulator to market Linagliptin and Metformin Hydrochlori12-10-2018
12-10-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
We enclose herewith a copy of press release dated October 12, 2018 titled 'Zydus receives tentative approval from the USFDA for Linagliptin and Metformin Hydrochloride Tablets'.12-10-2018
Shareholding for the Period Ended September 30, 2018
Cadila Healthcare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2018. For more details, kindly Click here10-10-2018
Statement Of Investor Complaints For The Quarter Ended September 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0770 Name of the Signatory :- Upen ShahDesignation :- Company Secretary and Compliance Officer09-10-2018
Statement Of Investor Complaints For The Quarter Ended September 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0770 Name of the Signatory :- Upen ShahDesignation :- Company Secretary and Compliance Officer09-10-2018
Joint Half Yearly Compliance Certificate From The Company And RTA.
Joint Half Yearly Compliance Certificate from the Company and RTA.06-10-2018
Certificate From A Practicing Company Secretary For The Half Year Ended On September 30, 2018.
Certificate from a Practicing Company Secretary for the half year ended on September 30, 2018.06-10-2018
Company news: Zydus Cadila
Zydus Cadila has received the final approval from the USFDA to market exemestane tablets 25 mg. It will be manufactured at the group's formulations ma05-10-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Exemestane Tablets05-10-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
We hereby inform that the Company's Biologics manufacturing facility (Zydus Biologics) located at the Zydus Biotech Park in Ahmedabad has received an Establishment Inspection Report (EIR) from the USFDA signifying the successful closure of the audit. The plant had completed the USFDA audit from 14th August to 24th August 2018 with Zero 483 observations.04-10-2018